

Day 3 May 24 (Fri.)

Plenary Session Scientific Program Educational Session Free Papers(Oral) Social Event English Session

		7:00	8:00	9:00	10:00	11:00	12:00	13:00	14:00	15:00	16:00	17:00	18:00	19:00	20:00	21:00	
Osaka International Convention Center	Room1 Large Hall (5F)		New Guideline 02 Guideline for Parkinson disease				LS-24 Takeda Pharmaceutical Company Limited		SPL Semi-Plenary Lecture		Symposium 24 Potential disease modifying therapies for Parkinson disease						
	Room2 Small Hall (5F)		LM-07 Lecture Marathon 07		LM-08 Lecture Marathon 08		O-25 Epilepsy2			LM-09 Lecture Marathon 09		LM-10 Lecture Marathon 10					
	Room3 Conference Room 1003 (10F)		Hot Topics 08 Treatable cerebellar ataxias			O-26 Dementia (INPH and others)		LS-25 Eisai Co., Ltd.		SL-02 Special Lecture 02		SL-03 Special Lecture 03					
	Room4 Conference Room 1001-1002 (10F)		Special Session 05 Let's start the basic research even after the clinical training by the presidents of scientific societies			O-27 Neuroimaging		LS-26 Cosmic Corporation Co., Ltd.		Symposium 25 New drug development and the change of treatment strategy in MG							
	Room5 Conference Room 1005-1007 (10F)		Symposium 20 Diagnosis and Treatment of Duropathies			O-28 Peripheral Neuropathy/ Metabolic disorders2		LS-27 Biogen Japan Ltd.		Symposium 26 Pregnancy planning and outcome in neuroimmunological disorders			ES-03 FUJIFILM Toyama Chemical Co., Ltd.				
	Room6 Conference Room 1009 (10F)		East Asian Neurology Forum 01 GBS in Asia			O-29 Neuroimmunology 1 (Basic Research)		LS-28 Sumitomo Dainippon Pharma Co.,Ltd		Symposium 27 Current topics in Guillain-Barré syndrome - from pathophysiology to clinical features			ES-04 Biogen Japan Ltd. / Eisai Co., Ltd.				
	Room7 Conference Room 1008 (10F)		International Education Course 04 CVD update			O-30 Dementia (Epidemiology and prevention)		LS-29 Chugai Pharmaceutical Co., Ltd.		Symposium 28 New concepts of glia and brain homeostasis: key missing pieces in the puzzle of neurological disorders							
	Room8 Conference Room 1004 (10F)					O-31 Clinical Neurophysiology2		LS-30 Medtronic Japan Co., Ltd.									
	Room9 Conference Hall (12F)		Symposium 21 A compass for deciphering the pathophysiology of migraine			O-32 Cerebrovascular disease (Clinical research 3)		LS-31 FP Pharmaceutical Corporation		Symposium 29 Drug development by open innovation with pharmaceutical company							
	Room10 Grande Toque (12F)		Symposium 22 Crosstalk between brain and liver			O-33 Clinical trial and Regenerative medicine2		LS-32 Novartis Pharma K.K.		Hot Topics 09 Critical care in epilepsy			ES-05 DAIICHI SANKYO Co.,Ltd. / UCB Japan Co.,Ltd.				
	Room11 Conference Room 1202 (12F)		Symposium 23 What is the first thing that the neurologist do when there is a disaster?			O-34 Parkinsonism and Related disorders (therapeutics)		LS-33 Mitsubishi Tanabe Pharma Corporation		Symposium 30 To the ocean of Brain visualization research							
	Room12 Conference Room 1101-1102 (11F)					O-35 Myopathy2		LS-34 Bayer Yakuhin, Ltd.		LB Late Breaking Symposium							
	Room13 Conference Room 801-802 (8F)		East Asian Neurology Forum 02 Hot Topics in Neurology: EANF 2019 (1)			O-36 Neuropathology		LS-35 AbbVie GK		East Asian Neurology Forum 03 Hot Topics in Neurology: EANF 2019 (2)							
	Room14 Conference Room 701-702 (7F)					O-37 Cerebellar ataxia2 (MSA and others)		LS-36 Novartis Pharma K.K. Medical Division									
Poster Session Event Hall (3F)		Poster Preparation					Poster Round					Poster Session		Poster Removal			

DAY 3